Astellas
Astellas’ Izervay Shows Prolonged Efficacy in 2-Year Study for Geographic Atrophy Treatment
Astellas made a significant acquisition of Iveric Bio earlier this year, primarily motivated by the potential of Iveric’s geographic atrophy ...
Padcev-Keytruda Combo Doubles Survival in First-Line Bladder Cancer Trial (ESMO 2023)
ESMO 2023: LBA6 Exciting results from the EV-302 phase 3 trial suggest that the partnership between Seagen and Astellas’ antibody-drug ...
Astellas launches TV campaign for Veozah, a new drug to treat hot flashes and other menopause symptoms
Astellas is revving up its efforts to transform the menopause drug Veozah into a standout product, and they’ve just hit ...
Apellis’ GA Drug Syfovre Displays Signs of Recovery Amid Challenges
Apellis Pharmaceuticals, which recently faced workforce reductions due to concerns surrounding its groundbreaking geographic atrophy (GA) drug, Syfovre, is reporting ...
Eric Stonestreet, ‘Modern Family’ Actor, Joins Forces with Astellas’ Iveric Bio to Launch Vision Health Awareness Initiative
Iveric Bio, an Astellas-acquired biotech company, has initiated a compelling awareness campaign for a disease it recently gained FDA approval ...
Astellas claims positive results for Izervay in geographic atrophy but remains vague on data
Astellas, having recently secured FDA approval for its drug Izervay to treat geographic atrophy (GA), is now in direct competition ...
Astellas Buys $50M Stake in Poseida, Boosting Gene Therapy Pipeline
Source – Poseida Therapeutics Japanese pharmaceutical company Astellas is making a strategic move by investing $50 million to acquire an ...
With the PeptiDream agreement, Astellas incorporates protein degraders
Source – Astellas Astellas has continued its focus on protein degrader drugs, announcing its second partnership in this category in ...
Astellas Faces Setback in the US Patent Trial for Myrbetriq
Source – Astellas An important patent that Astellas has on the urinary incontinence medicine Myrbetriq has been declared invalid by ...
